STOCK TITAN

Tandem Diabetes Stock Price, News & Analysis

TNDM Nasdaq

Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.

Tandem Diabetes Care (TNDM) delivers innovative insulin management solutions through advanced pump technology and connected diabetes care platforms. This news hub provides investors and healthcare professionals with timely updates on corporate developments, product milestones, and regulatory progress.

Access official press releases covering quarterly financial results, new product clearances, and strategic partnerships alongside analysis of market trends impacting diabetes care technology. Our curated collection ensures you stay informed about pump software updates, clinical trial outcomes, and international expansion efforts.

Key updates include FDA submissions, insulin delivery system enhancements, and operational developments across global markets. Bookmark this page for direct access to Tandem Diabetes' latest announcements, including pump compatibility improvements and user experience initiatives that shape modern diabetes management.

Rhea-AI Summary

Tandem Diabetes Care (NASDAQ: TNDM) is set to release its second quarter 2021 results on August 4, 2021, after market close. A conference call will follow at 4:30 PM ET to discuss financial and operational outcomes. Investors can join via a toll-free number or webcast. The company focuses on innovative insulin delivery solutions, with its flagship product being the t:slim X2™ insulin pump, which supports remote updates and integrated glucose monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
-
Rhea-AI Summary

Tandem Diabetes Care (NASDAQ: TNDM) recently showcased positive real-world data regarding its t:slim X2 insulin pump with Control-IQ technology at the American Diabetes Association's 81st Scientific Sessions. The findings indicate statistically significant glycemic improvements and enhanced quality of life for users, including diverse populations. Notably, disparities in glycemic outcomes by ethnicity were observed, but improvements were consistent across all groups. Key presentations highlighted the efficacy of Control-IQ in managing diabetes and its impact on users' daily lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) showcased successful real-world use data of its t:slim X2™ insulin pump with Control-IQ™ technology at the ATTD conference. Over 9,000 users experienced significant improvements in time in range (TIR) for diabetes management over 12 months. Dr. Jordan Pinsker emphasized the technology's real-world effectiveness and the positive impact on patients' quality of life. Additional studies indicated a median TIR of 73.6%, with high automation rates and low incidences of hypoglycemia, reflecting strong performance and user satisfaction with the device.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
Rhea-AI Summary

Tandem Diabetes Care, Inc. (TNDM) reported a strong first quarter of 2021, with worldwide pump shipments increasing 46% to 25,352 units and sales rising 44% to $141 million, compared to Q1 2020. Gross profit improved to $73.3 million, and Adjusted EBITDA reached $13.2 million. The company's net loss narrowed to $5 million from $14.9 million year-over-year. Tandem updated its 2021 sales guidance, now estimating $625-$640 million, marking a growth of 25-28% year-over-year. International sales are projected at $125-$130 million, reflecting a 50-56% increase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in three upcoming virtual investor conferences. Management will provide updates during:

  • BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 PM ET
  • Berenberg Conference USA 2021 on May 18, 2021, at 3:00 PM ET
  • UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 PM ET

These presentations will be webcast live and available for 30 days on the company's Investor Center website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
-
Rhea-AI Summary

CeQur has completed an oversubscribed $115 million equity financing to support commercial plans for its insulin-delivery device, CeQur Simplicity. The funds will enhance market development, initiate a phased launch in 2021, and scale manufacturing. CeQur Simplicity is FDA cleared and CE-marked, designed to replace multiple daily injections for over 3 million Americans. Clinical studies show significant improvement in insulin regimen adherence and glycemic control. The device targets a $7.5 billion U.S. market, aiming to ease insulin delivery for diabetes patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its first quarter 2021 results after market close on May 5, 2021. A conference call will follow at 4:30 PM ET to discuss the financial and operational results. Shareholders and interested parties can access details via dial-in numbers or through a live webcast. Tandem Diabetes is known for its innovative insulin delivery solutions, particularly the t:slim X2™ insulin pump that features remote software updates and integrated continuous glucose monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced management will present a company update at two upcoming virtual investor conferences. The presentations are scheduled for the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 PM ET and the Oppenheimer’s 31st Annual Healthcare Conference on March 17, 2021, at 2:30 PM ET. The updates will be webcast live, with an archive available for 30 days on Tandem's Investor Center website. This showcases Tandem's commitment to transparency and engagement with investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
conferences
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has appointed Jordan Pinsker, MD, as Vice President and Medical Director, effective April 26, 2021. Dr. Pinsker, a renowned pediatric endocrinologist, previously led artificial pancreas research at Sansum Diabetes Research Institute, where he directed clinical trials for automated insulin delivery systems. His extensive experience in diabetes care and technology aligns with Tandem's mission to enhance insulin therapy management. The leadership addition aims to drive innovation in closed-loop insulin delivery and improve outcomes for individuals with diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
management
Rhea-AI Summary

Tandem Diabetes Care reported strong financial results for Q4 and FY 2020, with worldwide pump shipments increasing 67% to 32,685 and sales rising 55% to $168.1 million compared to Q4 2019. For the full year, sales reached $498.8 million, a 38% increase, while the gross profit improved 34% to $260.5 million. The company anticipates 20-23% sales growth for 2021, estimating revenue between $600 million and $615 million, with a gross margin of approximately 55%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags

FAQ

What is the current stock price of Tandem Diabetes (TNDM)?

The current stock price of Tandem Diabetes (TNDM) is $11.93 as of August 22, 2025.

What is the market cap of Tandem Diabetes (TNDM)?

The market cap of Tandem Diabetes (TNDM) is approximately 721.6M.
Tandem Diabetes

Nasdaq:TNDM

TNDM Rankings

TNDM Stock Data

721.64M
66.87M
0.95%
121.22%
12.95%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
San Diego